Genetically Reduced Antioxidative Protection and Increased Ischemic Heart Disease Risk: The Copenhagen City Heart Study

138Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Background-Extracellular superoxide dismutase (EC-SOD) is an antioxidative enzyme found in high concentrations in the arterial wall. Two to three percent of all people in Denmark carry an R213G substitution, which increases plasma concentration 10-fold. This may reduce arterial wall EC-SOD concentrations, increase intimal LDL oxidation, and therefore may accelerate atherogenesis. Our primary hypothesis was that EC-SOD-R213G predisposes to ischemic heart disease (IHD). The secondary hypothesis was that EC-SOD-R213G offers predictive ability with respect to IHD beyond that offered by measurements of plasma EC-SOD and autoantibodies against oxidized LDL (oxLDL). Methods and Results-The primary hypothesis was tested in a prospective, population-based study of 9188 participants from The Copenhagen City Heart Study with 956 incident IHD events during 23 years of follow-up and retested cross-sectionally with independent case populations of patients with IHD (n=943) or ischemic cerebrovascular disease (ICVD) (n=617). Case populations were compared with unmatched IHD/ICVD-free control subjects from The Copenhagen City Heart Study (n=7992). The secondary hypothesis was tested by using a nested case-control study comparing patients with IHD (n=956) with age- and gender-matched control subjects (n=956). Age- and gender-adjusted relative risk for IHD in heterozygotes (n=221, 2.4%) versus noncarriers (n=8965, 97.6%) was 1.5 (95% CI, 1.1 to 2.1). Retesting confirmed this: Age- and gender-adjusted odds ratios for IHD was 1.4 (1.0 to 2.0) and for ICVD 1.7 (1.1 to 2.7). Additional adjustment for plasma EC-SOD produced an odds ratio for IHD in heterozygotes versus noncarriers of 9.2 (1.2 to 72), whereas adjustment for autoantibodies against oxLDL produced an odds ratio of 2.5 (1.2 to 5.3). Conclusions-Heterozygosity for EC-SOD-R213G is associated with increased IHD risk. Genotyping offers predictive ability with respect to IHD beyond that offered by plasma EC-SOD and autoantibodies against oxLDL.

References Powered by Scopus

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial

974Citations
N/AReaders
Get full text

The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?

407Citations
N/AReaders
Get full text

Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus

396Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mendelian randomization: Geneticanchorsfor causal inference in epidemiological studies

2735Citations
N/AReaders
Get full text

Pathophysiology of sleep apnea

1590Citations
N/AReaders
Get full text

Superoxide dismutases: Role in redox signaling, vascular function, and diseases

1549Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Juul, K., Tybjærg-Hansen, A., Marklund, S., Heegaard, N. H. H., Steffensen, R., Sillesen, H., … Nordestgaard, B. G. (2004). Genetically Reduced Antioxidative Protection and Increased Ischemic Heart Disease Risk: The Copenhagen City Heart Study. Circulation, 109(1), 59–65. https://doi.org/10.1161/01.CIR.0000105720.28086.6C

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

61%

Professor / Associate Prof. 5

22%

Researcher 4

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

46%

Agricultural and Biological Sciences 9

32%

Biochemistry, Genetics and Molecular Bi... 6

21%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free